1. Home
  2. EZPW vs CAPR Comparison

EZPW vs CAPR Comparison

Compare EZPW & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EZCORP Inc. Non Voting

EZPW

EZCORP Inc. Non Voting

HOLD

Current Price

$33.70

Market Cap

1.6B

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$28.89

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EZPW
CAPR
Founded
1989
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
1996
2011

Fundamental Metrics

Financial Performance
Metric
EZPW
CAPR
Price
$33.70
$28.89
Analyst Decision
Buy
Strong Buy
Analyst Count
3
8
Target Price
$30.67
$44.63
AVG Volume (30 Days)
670.3K
1.1M
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
29.09
N/A
EPS
1.17
N/A
Revenue
$747,954,000.00
N/A
Revenue This Year
$25.40
N/A
Revenue Next Year
$11.33
$3.31
P/E Ratio
$28.55
N/A
Revenue Growth
2.39
N/A
52 Week Low
$12.89
$4.30
52 Week High
$37.13
$40.37

Technical Indicators

Market Signals
Indicator
EZPW
CAPR
Relative Strength Index (RSI) 61.86 42.38
Support Level $31.76 $27.98
Resistance Level $37.13 $30.06
Average True Range (ATR) 1.44 1.87
MACD -0.19 -0.39
Stochastic Oscillator 39.71 26.58

Price Performance

Historical Comparison
EZPW
CAPR

About EZPW EZCORP Inc. Non Voting

EZCORP Inc is a United States-based company engaged in offering pawn loans in the United States and Mexico. It also offers short-term unsecured loans and other consumer financial products, and buys and sells second-hand goods. The operating segments of the company are U.S. Pawn, Latin America Pawn, and Other Investments. The U.S. Pawn segment includes all pawn activities in the United States. The Latin America Pawn segment includes all pawn activities in Mexico and other parts of Latin America. The company generates revenue from merchandise sales, jewelry scrapping sales, and pawn service charges, of which key revenue is derived from the merchandise sales, which are mainly collateral forfeited from pawn lending operations and used merchandise purchased from the customers.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: